An open label, long-term extension study to evaluate the safety and efficacy of CRN00808 in subjects with acromegaly (ACROBAT ADVANCE) - CRN00808-05

Crinetics Pharmaceuticals Inc.0 sites31 target enrollmentJune 28, 2024

Overview

No summary available.

Registry

who.int

Start Date

June 28, 2024

End Date

TBD

Last Updated

last year

Study Type

Interventional clinical trial of medicinal product

Sex

All

Sponsor

•1\. Completed one of the parent studies (Acrobat Evolve (CRN00808\-02\) or Acrobat Edge (CRN00808\-03\)), 2\. Females must be non\-pregnant and non\-lactating either surgically sterile, post\-menopausal, or using effective method(s) of birth control., 3\. Willing to provide signed informed consent

•1\. Clinically significant concomitant disease including, but not limited to, cardiovascular disease; moderate or severe renal insufficiency; or significant liver disease (including cirrhosis), 10\. Subjects with clinically significant abnormal findings during the Screening Period, and any other medical condition(s) or laboratory findings that, in the opinion of the Investigator, might jeopardize the subject's safety or ability to complete the study, 2\. Pituitary radiation since completing participation in parent studies, 3\. History or presence of malignancy except adequately treated basal cell and squamous cell carcinomas of the skin within the past 5 year, 4\. Positive test at Screening for HIV, hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCV\-Ab)., 5\. History of alcohol or substance abuse in the past 12 months, 6\. Use of any investigational drug (other than paltusotine) within the past 30 days or 5 half\-lives, whichever is longer before Screening, 7\. Any condition that in the opinion of the investigator would jeopardize the subject's appropriate participation in this study., 8\. Cardiovascular conditions or medications associated with prolonged QT or those which predispose subjects to heart rhythm abnormalities, 9\. Subjects with symptomatic cholelithiasis